Business Context and Reporting Period
Company: Myriad Genetics, Inc. (MYGN)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Preliminary results for the quarter and full year ended December 31, 2025.
Key Financial Metrics and Volume Data
The filing provides preliminary volume information but does not disclose specific dollar amounts for revenue, profit, cash flow, margins, debt, or liquidity in the text provided.
- Total Test Volumes (2025): Approximately 1.5 million tests.
- Hereditary Cancer Testing: Approximately 7% year-over-year growth.
- Mental Health Testing: Approximately 6% year-over-year growth.
- Prenatal Health Testing: Approximately 4% year-over-year decrease.
Material Changes Versus Prior Period
Compared to the prior year, total test volume increased by 1%. This aggregate growth was driven by double-digit percentage increases in hereditary cancer and mental health testing segments, partially offset by a decline in prenatal health testing volumes.
Guidance, Outlook, and Risks
Guidance: The Company introduced full-year 2026 financial guidance (specific figures not included in this filing text).
Outlook: Management expects continued volume growth in cancer and mental health testing.
Risks and Contingencies:
- Preliminary Nature: Financial results are preliminary and subject to change following normal accounting procedures and external audit.
- Forward-Looking Statements: Actual results may differ materially from expressed statements due to risks and uncertainties.
Investor Verification Checklist
- Verify the specific dollar values for 2025 revenue and profit in the full press release (Exhibit 99.1).
- Confirm the detailed 2026 financial guidance figures not listed in this summary.
- Review the final audited financial statements to confirm the preliminary volume and financial data.
- Assess the impact of the 4% decline in prenatal health testing on overall margin trends.